MedTrace Logo

A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants

NCT05434091 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-09-07

No results posted yet for this study

Summary

The purpose of the study is to learn about the safety, tolerability (the extent to which side effects can be tolerated), and plasma pharmacokinetics (PK) (PK helps us understand how the drug is changed and eliminated from body after you take it) of PF-07291177 after administration of escalating, single, doses by mouth.

Conditions

  • Healthy Participants

Interventions

DRUG

PF-07291177

PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined

DRUG

Placebo

Matching placebo will be prepared as an oral solution and/or suspension given in each cohort

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-15
Primary Completion
2023-03-29
Completion
2023-03-29
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05434091 on ClinicalTrials.gov